TYME stock is making solid gains this morning after the biotechnology company Tyme Technologies Inc (NASDAQ:TYME) announced encouraging data from its phase 2 study of SM-88.
Solid News for Tyme TechnologiesThe company released encouraging data from the Phase 2 trial of its medicine SM-88, which is meant for treating pancreatic cancer, and when such an update is published, the stock generally moves. Trading volume is generally a good indication of how much interest a stock is generating at a particular time interval, and TYME stock’s volume went through the roof in early trade.
...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.